GSK Announces Positive Topline Data on Co-Administration of AREXVY and SHINGRIX
Co-administration of the RSV and shingles adjuvanted vaccines was well tolerated, with acceptable reactogenicity and safety ...
BioSpace2d
GSK Builds Combo Case for RSV, Shingles Shots With Phase III Data
If approved, the co-administration of Arexvy and Shingrix could provide a more convenient vaccination regimen for patients ...
Renal & Urology News1d
GSK Reports Findings on Coadministered RSV and Shingles Vaccines
Topline results were announced from a phase 3 study assessing the immune response following coadministration of Arexvy and Shingrix.
Zacks.com on MSN2d
GSK Meets Study Goal for Co-Administered RSV-Shingles Vaccines
Data from a late-stage study shows that co-administering GSK's RSV and Shingles vaccines together was as effective as giving ...
FiercePharma3d
GSK touts co-administration data for RSV, shingles vaccines as narrowed CDC guidance threatens sales
In the study, co-administration of GSK's RSV vaccine Arexvy and shingles shot Shingrix elicited non-inferior immune responses ...
GSK posts late-stage trial win for co-administered RSV and shingles vaccines
GSK (GSK) reached the main goal in a Phase 3 trial for its RSV shot, Arexvy co--administered with Shingles vaccine Shingrix.
GSK's Respiratory Syncytial Virus Vaccine Given Together With Shingles Shot Shows Non-Inferior Immune Response In Older Adults
GSK plc (NYSE:GSK) released topline data from the phase 3 trial in adults 50 years and older evaluating the immunogenicity, ...
Morningstar3d
GSK Announces Positive Topline Data on Co-Administration of AREXVY and SHINGRIX
2 SHINGRIX is approved for the prevention of shingles (herpes zoster) in adults aged 50 years and older. AREXVY is approved for the prevention of lower respiratory tract disease (LRTD) caused by ...